← Back to patent-cliff list
NRP-2945
Tier C — Watch / tradeNRP-2945
Neuren Pharmaceuticals Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：CXCR4
Indications (approved)：Lennox-Gastaut syndrome, 颞叶癫痫, 失神发作, Amyotrophic lateral sclerosis, Angelman综合征, Rett syndrome
Regional status
US
-
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NRP-2945?
Approved indications include: Lennox-Gastaut syndrome, 颞叶癫痫, 失神发作, Amyotrophic lateral sclerosis, Angelman综合征, Rett syndrome.
When does the NRP-2945 patent expire?
No public expiry year is available for NRP-2945 yet; this page updates once verified.
How do I get a quote for NRP-2945 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-08